Application Note

Apheresis Variability Control In Cell Therapy Manufacturing

Source: Cytiva
Cancer cells GettyImages-1310861779

T cell receptor (TCR)-based treatments, such CAR-T cell therapy, have become a focus of research and could eventually play an important role in standard of care for cancer. Making these treatments — and the processes used to create them — adaptable to many patients remains a key challenge in standardizing immunotherapies, due to inherent and significant source product variability.

Peripheral blood collection with apheresis processing is a preferred method for obtaining patient source material for cell therapies, as it is minimally invasive and results in the collection of a large number of cells. This article contains a collection of resources and information about apheresis products and their characteristics, manner of collection, and processing. Explore our best practices for apheresis collection and obtention of enriched product for cell therapies.

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: